Now only in ₹15 trading promotor holding or fundamentals are very strong Next LAURUSLABS shar, MARKETCAP ₹1,495 Cr and share holding pattern of promoters in 2024 is above 50%.Company sale extend march 2021 to march 2023 over 222 and Expenses 202
Most recommended visit : 2024 INDIAN RAILWAY FINANCE SHARE PRICE TARGET
SYNCOM FORMULATIONS 2024 T0 2032 BIG MOVE
SYNCOM FORMULATIONS is a generic pharmaceutical company, it is manufacturing generic medicine or healthcare products, Syncom formulation was established in 1995 by Kedarmal Shankarlal Bankda, it is a key player of generic medicines which sells more than 400 products in 15 countries.
MANUFACTURING : Syncom manufactures more then 400 product in various dosage like Ampoule Injection, Capsules, Dry powder injections, Tablets, Liquid oral, Dry Syrup, Suspensions, Ointments, ORS, Creams, Gels
Most recommended visit : IFCI SHARE PRICE TARGET 2024
Most recommended visit : IDFC FIRST BANK SHARE PRICE TARGET 2024
SYNCOM FORMULATIONS SHARE HOLDING PATTERNS
| SYNCOM FORMULATIONS | CLICK4INVESTING.COM |
|---|---|
| MARKET CAP | ₹1,495 Cr |
| HIGH/LOW | 18.6/4.55 |
| STOCK P/E | 64.8 |
| ROE | 8.42% |
| ROCE | 9.70% |
| BOOK VALUE | ₹2.87 |
| DIVEDEND YIELD | 0.00% |
| FACE VALUE | ₹1.00 |
Most recommended visit : Hindustan Aeronautics Ltd(2024)
ONE YEAR CHART PATTERN OF SYNCOM FORMULATIONS
IMAGE SOUCE CREDIT : TRADING VIEW
Most recommended visit : BAJAJ FINANCE SHARE PRICE TARGET
SHARE HOLDING PATTERN
| HOLDINGS | DEC 2020 | DEC 2021 | DEC 2022 | MARCH 2023 | JUNE 2023 | SEP 2023 |
|---|---|---|---|---|---|---|
| PROMOTERS | 40.48% | 44.01% | 50.57% | 50.57% | 50.57% | 50.57% |
| FIIS | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| PUBLIC | 59.52% | 55.99% | 49.43% | 49.44% | 49.44% | 49.44% |
| GOVERNMENT | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
KEYPOINTS : Despite being a micro cap company and selling around 400 products with consistency ,generic product across 15 countries it is about pride the company managements , Whether it is known that the company is dominating in its sector or these key points are the sign of a successful company, all these facts make SYMCOM Formulations a strong micro cap company. The company is investing in different ways for its future growth. Company revenue and manufactured goods and trades TABLETS 65%,INJECTABLES 19% ,CAPSULES 7%, OINMENT 4% ,LIQUIDS 4% OTHERS 1%.
GROWTH : Compound sales growth 3years 3% , five year 7% , ten years 7% and return on Equity last three years 12% , five years 11% or ten years 10%. Companies liabilities is increased in march 2012 to sep2023 over 291 Cr.
POSITIVITY : SYMCOM assets ,Reserves and investment may increased last 3 years, It is a penny stock which is regularly traded in both the NSE and BSE segments of the Indian Exchange with large scale volumes. Many experts believe that in the coming days, the market value of the share will be seen increasing rapidly because the share is very old and reliable.
Most recommended visit : INFIBEAM AVENUES PRICE TARGET
SYNCOM FORMULATIONS OF PROS and CONS
| PROS | CONS |
|---|---|
| * Promoter holdings above 50% | * last 3 years company gave low return in equity segment |
| * 400 products over 15 countries sale | * company gave poor sales growth in last five yearf |
SYNCOM FORMULATIONS PRICE TAREGET 2024 T0 2032 “A GUESS CAN BE” MADE“
| YEAR | MANIMUM PRICE TARGET | MAXIMUM PRICE TARGET | AVERAGE PRICE TARGET |
|---|---|---|---|
| 2024 | ₹11.00 | ₹29.00 | ₹17.00 |
| 2025 | ₹ 27.00 | ₹37.00 | ₹33.00 |
| 2026 | ₹31.00 | ₹45.00 | ₹38,00 |
| 2027 | ₹42.00 | ₹62.00 | ₹57.00 |
| 2028 | ₹55.00 | ₹68.00 | ₹61.00 |
| 2029 | ₹65.00 | ₹77.00 | ₹71.00 |
| 2030 | ₹70.00 | ₹81.OO | ₹76.00 |
| 2031 | ₹79.00 | ₹93.00 | ₹90.00 |
| 2032 | ₹92.00 | ₹101.00 | ₹98.00 |
FAQ :
- IS SYNCOM FORMULATIONS MICRO CAP COMPANY !
- YES ! MARKET CAP IS ₹ 1,495 Cr ONLY
- SYNCOM FORMULATIONS WHICH TYPE OF COMPANY !
- IT IS GENERIC PHARMACEUTICAL COMPANY , MANUFACTURING GENERIC MEDECINE OR HEALTH CARE PRODUCTS.
- IS IT LISTED COMPANY !
- YES ! LISTED NSE OR BSE BOTH
- FOUNDER OF SYMCOM FORMULATIONS !
- Kedarmal Shankarlal Bankda IS FOUNDER OF SYMCOM FORMULATIONS
- DOES SYMCOM FORMULATIONS PAY DIVEDEND TO ITS INVESTOR !
- NO!
- IS SYMCOM FORMULATIONS A GENERIC PHARMA COMPANY !
- YES! IT IS A GENERIC COMAPANY
- WHAT IS THE HOLDING OF THE PROMOTERS SYMCOM FORMULATIONS !
- PROMOTERS HOLDINGS ABOVE 50%
Most recommended visit : HDFC BANK SHARE PRICE FIIS ENTRY 2024
4 thoughts on “SYNCOM FORMULATIONS 2024 T0 2032 PRICE”